Painiac

Total Rating:
0 / 0

1 Comment

    • Tue Feb 26th 08:11 AM | Rating: 0 0
      Commented on:
      A PR Virus for Pharmaceuticals
      From my perspective as a pain specialist, I am not surprised at the decline in trust. The oxycontin marketing model and subsequent success really opened my eyes to the extent that cash drives the system. While it was supposed to provide improvements in cancer care it was obvious to me that common back pain was the real target. The corruption of pain specialists to be part of their paid "speakers bureau" while a bold inciteful marketing move was ultimately bad for the specialty. Eventually the FDA fined them but not close to the amount of profits generated. Their legacy lives on in the increased forever addicted young opiate addicts. Perhaps it was one companies problem, but every pain product brought to market by other comapnies has tried to follow their marketing model.
      The gabapentin mismarketing was another example that pain specialists and eventually the public saw through (again large FDA fine). Here a marginally effective seizure drug was good for pain but the company did not test it that way until it was forced to do so.
      Today, suboxone is marketed as a addiction treatment but a good portion of its use is for pain. Again the company doesn't want todo the reasearch and the reps can't talk about it but they bring in speakers bureau docs to have their say.
      That being said, the ethics of the pharm business seem to be improving, but the survey shows that pharm is lying in the bed that they feathered. Complaining that they don't like the lumps in the mattress sounds like sour grapes from here.
      View article »
Loading...
Symbols:
Authors:
Quick Links:
Contribute an Article Become a Seeking Alpha Contributor

Transcripts

More Transcripts»